At Axial, our Microbial-Inspired Therapeutics® Platform is at the forefront of scientific innovation in the gut microbiome and its impact on human health. With the goal of improving patients’ lives our initial focus of this broadly applicable platform is on the microbiome’s role in conditions such as Autism Spectrum Disorder (ASD) and Parkinson’s disease by leveraging our understanding of the microbiome’s connection to the nervous system.

Our Science

Our scientific focus on the microbiome and its impact on human health represents a transformative therapeutic approach that has potential to treat diseases and disorders in ways never before possible.

Our Pipeline

We are advancing a pipeline of gut-targeted small molecule therapies in areas of significant unmet patient need including autism spectrum disorder and Parkinson’s disease, with early-stage programs in liver disease and oncology.

Latest News

January 5, 2024

Axial Therapeutics to Present at Upcoming Conferences

September 26, 2023

Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism

June 20, 2023

Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease